Get the Stockscreener App
1.84
3.66%
-0.07
Scisparc Ltd stock is traded at $1.84, with a volume of 164.24K.
It is down -3.66% in the last 24 hours and down -33.81% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$1.91
Open:
$1.99
24h Volume:
164.24K
Relative Volume:
0.03
Market Cap:
$6.03M
Revenue:
$1.31M
Net Income/Loss:
$-7.47M
P/E Ratio:
-0.2551
EPS:
-7.2117
Net Cash Flow:
$-5.11M
1W Performance:
+5.75%
1M Performance:
-33.81%
6M Performance:
+467.20%
1Y Performance:
+618.47%
1-Day Range:
$1.83
$2.015
1-Week Range:
$1.76
$2.26
52-Week Range:
$0.197
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
1.84 | 6.26M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech - MSN
SciSparc Shares Experience Pre-Bell Dip Following Quiet Session - timothysykes.com
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast - ts2.tech
Will SciSparc Ltd. stock outperform growth indexesJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
NeuroThera to acquire 55% stake in quantum computing bio data company - MSN
SciSparc Shares Slide After Revealing Plans to Acquire MUSE Endoscopic System IP - MSN
SciSparc’s NeuroThera Labs Eyes Quantum Leap with New Acquisition - TipRanks
SciSparc Ltd. Announces NeuroThera Labs' Planned Acquisition of Quantum Computing Bio Data Company - Quiver Quantitative
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - The Manila Times
SciSparc (Nasdaq: SPRC) NeuroThera signs term sheet for 55% quantum data stake - Stock Titan
SciSparc plans to enter GERD device market with IP portfolio acquisition - MSN
symbol__ Stock Quote Price and Forecast - CNN
SciSparc (SPRC) Stock Analysis Report | Financials & Insights - Benzinga
SciSparc stock tumbles after announcing MUSE system acquisition plans By Investing.com - Investing.com UK
SciSparc Ltd. (SPRC) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
SciSparc stock tumbles after announcing MUSE system acquisition plans - Investing.com
SciSparc to acquire MUSE endoscopic system patents from Xylo By Investing.com - Investing.com Nigeria
SciSparc to acquire MUSE endoscopic system patents from Xylo - Investing.com
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio - The Manila Times
Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio - marketscreener.com
SciSparc Ltd. Signs Agreement to Acquire Patents and Intellectual Property for Innovative MUSE™ Endoscopic System from Xylo Technologies Ltd. - Quiver Quantitative
Scisparc Plans On Entering The Multi-Billion-Dollar Gerd Device Market With Acquisition Of An Approved IP Portfolio - TradingView
SciSparc acquires Xylo Technologies' innovative endoscopic portfolio - Indian Pharma Post
SciSparc Ltd. (SPRC) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SciSparc Ltd. Announces $2.2 Million Securities Offering - The Globe and Mail
Form 424B5 SciSparc Ltd. - StreetInsider
Is SciSparc Ltd a good long term investmentStock Buyback Announcements & Free Tap Rapid Wealth - earlytimes.in
What analysts say about SciSparc Ltd stockMid Cap Growth Trends & Minimal Investment Trading Tips - earlytimes.in
SciSparc to acquire treasury of patents for medical endoscopy systems - MSN
SciSparc Shares Surge After Company Moves to Acquire GERD Treatment Technology - MSN
SciSparc’s Stock Slip: Investment Opportunity? - timothysykes.com
SciSparc Ltd. to Acquire Xylo’s Patents for Endoscopic Systems - TipRanks
[6-K] SciSparc Ltd. Current Report (Foreign Issuer) | SPRC SEC FilingForm 6-K - Stock Titan
SciSparc’s Patent Surge: Buy or Hold? - StocksToTrade
SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market - parameter.io
Why SciSparc Stock Is Gaining TodaySciSparc (NASDAQ:SPRC) - Benzinga
SciSparc to acquire endoscopic system patents from Xylo Technologies By Investing.com - Investing.com Nigeria
SciSparc Stocks Surge: A Strategic Leap Forward? - timothysykes.com
SciSparc stock soars after acquiring GERD treatment technology By Investing.com - Investing.com Nigeria
SciSparc stock soars after acquiring GERD treatment technology - Investing.com India
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):